BlossomHill Therapeutics (BLSM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$8.75
- Estimate
- -$0.77
- Surprise
- -1036.4%
- Score today
- 5.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
BlossomHill Therapeutics (BLSM) reported a wider loss than forecast — adjusted EPS of -$8.75 against the -$0.77 estimate (a 1036.4% shortfall).
Coverage in the report window
- Earnings Scheduled For September 18, 2026 — benzinga, 2026-09-18
- BlossomHill Therapeutics Q2 EPS $(8.75) — benzinga, 2026-09-18
Where TrendMatrix's rating stands now
TrendMatrix currently rates BLSM Sell at 5.9/10; no pre/post engine snapshot brackets this report.
What argues against it
- Quality below floor (3.3 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -39.6%), Material insider selling (14 sells, 0.68% of cap)
- Momentum score 2.8/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.47
- Price target
- $30.80
- Stop
- $19.04
- Upside to target
- +50.5%
- Reward-to-risk
- 3.4:1
Model outputs from TrendMatrix’s engine as of 2026-09-25 — shown for context, not personalized investment advice.
BLSM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $710.1M
- P/E (fwd)
- -5.6
- 52-week range
- $15.25–$27.99
- Off 52-week high
- 26.9%
- RSI (14)
- 51
- Volume vs avg
- 1.24×
- Score today
- 5.9/10